Degradation of amyloid-beta peptide: A key to Alzheimer pathogenesis, prevention and therapy

NeuroScience News

Volumn 3, Issue 5, 2000, Pages 52-62

  Saido, T C ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Alzheimer's disease; Amyloid peptide; Catabolism neutral endopeptidase; Enkephalinase; Neprilysin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE;

ALZHEIMER DISEASE; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REVIEW;

EID: 0033741650     PISSN: 10276599     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. The genetic causes of the tau and synucleinopathies
2. Quantitation of amyloid beta-protein (A-beta) in the cortex during aging and in Alzheimers-disease
3. Alzheimer's-disease as proteolytic disorders - Anabolism and catabolism of beta-amyloid
4. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in rive by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
5. The e280a presenilin 1 Alzheimer mutation produces increased A-beta-42 deposition and severe cerebellar pathology
6. Amyloid beta protein (A-beta) deposition in chromosome 14-linked Alzheimer's disease - Predominance of A-beta(42(43))
7. Predominant deposition of amyloidbeta(42(43)) in plaques in eases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene
8. Intracellular protein degradation in mammalian and bacterial cells
9. Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
10. Mutant-presenilin 2-transgenic mice: A large increase in the levels of Aβ42 is presumably associated with the low-density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin
11. Insulin degradation - Progress and potential
12. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme
13. Insulin-regulated β-amyloid trafficking: Stimulated secretion and reduced intracellular accumulation of Aβ in neuronal cell cultures
14. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase ill and coassociates with other phosphoproteins including the Lyn src-related kinase
15. Association of CD10 neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol-anchored proteins and Lyn kinase
16. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides
17. Damage-induced neuronal endopeptidase (DINE) is a unique metallopeptidase expressed An response to neuronal damage and activates superoxide scavengers
18. Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon
19. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology
20. Structure and functions of the 20s and 26s proteasomes
21. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease
22. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport
23. The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells
24. Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease
25. Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques
26. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse
27. The plasmin system is induced by and degrades amyloid-beta aggregates
28. Water-soluble A-beta (n-40, n-42) oligomers in normal and Alzheimer disease brains
29. Amyloid beta protein (Abeta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Abeta 40 or Abeta 42(43)
30. Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques
31. Amino-and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain
32. Isolation, chemical characterization, and quantitation of A-beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits
33. Quantification of modified amyloid beta peptides in Alzheimer-disease and Down-syndrome brains
34. Presenilin-1 mutations in Alzheimer's disease
35. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Downs syndrome
36. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimers-disease and Downs-syndrome brains
37. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
38. Aβ40 and Aβ42 clearance in a transgenic mouse model expressing human apoE3 and apoE4
39. Apolipoprotein J and Alzheimer's amyloid beta solubility
40. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40 - Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer
41. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
42. Alzheimer's disease: The value of transgenic and gene targeted models